Jan-Philipp Weber1, Martin Wermke2. 1. Klinik 1 für Innere Medizin, Universitätsklinikum Köln, Köln, Deutschland. 2. Medizinische Fakultät, Medizinische Klinik 1 und Nationales Centrum für Tumorerkrankungen, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. Martin.wermke@ukdd.de.
Abstract
BACKGROUND: Although the treatment and prognosis of many solid tumor types in the metastatic situation could be considerably improved during the last decade, for a long time no significant progress in the treatment of small cell lung cancer (SCLC) could be achieved. OBJECTIVE: The aim of this article is to describe the current treatment standard for SCLC and to discuss potential approaches for further improvement. METHODS: A selective literature search was carried out in PubMed and abstract lists of relevant conferences. RESULTS: Given the recent approval of two immunochemotherapy regimens based on the combination of anti-PD-L1 antibodies with platinum-etoposide, the therapeutic standard in the first line treatment of metastasized SCLC has finally been improved for the first time in three decades; however, the overall survival benefit has been modest with an improvement of just 2-3 months. In advanced lines of treatment no new approaches could so far show improved outcome compared with established chemotherapy protocols, such as topotecan and combinations of anthracycline, cyclophosphamide and vincristine. The slow progress in SCLC compared to non-SCLC, has been attributed to the complex biology, the exceptionally high proliferation rate and rapid development of resistance to chemotherapy. Increasing knowledge on the molecular and immunological principles of SCLC is increasingly opening up novel treatment approaches. CONCLUSION: There has finally been a slow but clinically meaningful progress in the treatment of SCLC. Patients should be included in clinical trials at the latest after second line treatment, in order to accelerate the speed of the expansion of treatment options.
BACKGROUND: Although the treatment and prognosis of many solid tumor types in the metastatic situation could be considerably improved during the last decade, for a long time no significant progress in the treatment of small cell lung cancer (SCLC) could be achieved. OBJECTIVE: The aim of this article is to describe the current treatment standard for SCLC and to discuss potential approaches for further improvement. METHODS: A selective literature search was carried out in PubMed and abstract lists of relevant conferences. RESULTS: Given the recent approval of two immunochemotherapy regimens based on the combination of anti-PD-L1 antibodies with platinum-etoposide, the therapeutic standard in the first line treatment of metastasized SCLC has finally been improved for the first time in three decades; however, the overall survival benefit has been modest with an improvement of just 2-3 months. In advanced lines of treatment no new approaches could so far show improved outcome compared with established chemotherapy protocols, such as topotecan and combinations of anthracycline, cyclophosphamide and vincristine. The slow progress in SCLC compared to non-SCLC, has been attributed to the complex biology, the exceptionally high proliferation rate and rapid development of resistance to chemotherapy. Increasing knowledge on the molecular and immunological principles of SCLC is increasingly opening up novel treatment approaches. CONCLUSION: There has finally been a slow but clinically meaningful progress in the treatment of SCLC. Patients should be included in clinical trials at the latest after second line treatment, in order to accelerate the speed of the expansion of treatment options.
Authors: M Fukuoka; K Furuse; N Saijo; Y Nishiwaki; H Ikegami; T Tamura; M Shimoyama; K Suemasu Journal: J Natl Cancer Inst Date: 1991-06-19 Impact factor: 13.506
Authors: Jonathan W Goldman; Mikhail Dvorkin; Yuanbin Chen; Niels Reinmuth; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Oleksandr Voitko; Artem Poltoratskiy; Santiago Ponce; Francesco Verderame; Libor Havel; Igor Bondarenko; Andrzej Każarnowicz; György Losonczy; Nikolay V Conev; Jon Armstrong; Natalie Byrne; Piruntha Thiyagarajah; Haiyi Jiang; Luis Paz-Ares Journal: Lancet Oncol Date: 2020-12-04 Impact factor: 41.316
Authors: Thomas H Fink; Rudolf M Huber; David F Heigener; Corrina Eschbach; Cornelius Waller; Ernst U Steinhauer; Johann C Virchow; Frank Eberhardt; Hans Schweisfurth; Michael Schroeder; Thomas Ittel; Simone Hummler; Norbert Banik; Thomas Bogenrieder; Thomas Acker; Martin Wolf Journal: J Thorac Oncol Date: 2012-09 Impact factor: 15.609
Authors: Fiona Blackhall; Kevin Jao; Laurent Greillier; Byoung Chul Cho; Konstantin Penkov; Noemi Reguart; Margarita Majem; Kristiaan Nackaerts; Konstantinos Syrigos; Karin Hansen; Wolfgang Schuette; Jeremy Cetnar; Federico Cappuzzo; Isamu Okamoto; Mustafa Erman; Seppo W Langer; Terufumi Kato; Harry Groen; Zhaowen Sun; Yan Luo; Poonam Tanwani; Laura Caffrey; Philip Komarnitsky; Niels Reinmuth Journal: J Thorac Oncol Date: 2021-02-16 Impact factor: 15.609
Authors: Leora Horn; Aaron S Mansfield; Aleksandra Szczęsna; Libor Havel; Maciej Krzakowski; Maximilian J Hochmair; Florian Huemer; György Losonczy; Melissa L Johnson; Makoto Nishio; Martin Reck; Tony Mok; Sivuonthanh Lam; David S Shames; Juan Liu; Beiying Ding; Ariel Lopez-Chavez; Fairooz Kabbinavar; Wei Lin; Alan Sandler; Stephen V Liu Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Carl M Gay; C Allison Stewart; Elizabeth M Park; Lixia Diao; Sarah M Groves; Simon Heeke; Barzin Y Nabet; Junya Fujimoto; Luisa M Solis; Wei Lu; Yuanxin Xi; Robert J Cardnell; Qi Wang; Giulia Fabbri; Kasey R Cargill; Natalie I Vokes; Kavya Ramkumar; Bingnan Zhang; Carminia M Della Corte; Paul Robson; Stephen G Swisher; Jack A Roth; Bonnie S Glisson; David S Shames; Ignacio I Wistuba; Jing Wang; Vito Quaranta; John Minna; John V Heymach; Lauren Averett Byers Journal: Cancer Cell Date: 2021-01-21 Impact factor: 31.743